Condition
Primary Lymphedema
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Completed2
Not Yet Recruiting1
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06327412Not ApplicableNot Yet RecruitingPrimary
The Effects of Aerobic Exercise in Patients With Primary Lower Extremity Lymphedema
NCT02595996Phase 2TerminatedPrimary
Propranolol Dose Escalation in Lymphedema in Patients
NCT04919655UnknownPrimary
Primary Lymphedema and Mutation CELSR1 (Cadherin EGF LAG Seven-pass G-type Receptor 1)
NCT02988479CompletedPrimary
Out-of Pocket Payments in Patients With Lymphedema
NCT01748604Not ApplicableCompletedPrimary
Physical Therapies in the Decongestive Treatment of Lymphedema
Showing all 5 trials